Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Praxis Precision Medicines, Inc. (NASDAQ: PRAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Praxis is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and its filings offer detailed insight into the development and financing of its precision neuroscience portfolio.
Through Forms 8-K, Praxis reports material events such as topline clinical results, regulatory interactions and capital markets transactions. Recent 8-K filings describe positive Phase 3 Essential3 data for ulixacaltamide in essential tremor, EMBOLD study outcomes for relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs), and RADIANT study data for vormatrigine in focal onset seizures and generalized epilepsy. Other 8-Ks outline pre-New Drug Application (NDA) meetings with the U.S. Food and Drug Administration (FDA), alignment on registrational pathways for elsunersen in early-onset SCN2A-DEE, and details of underwritten public offerings and at-the-market equity programs.
Investors can also use this page to monitor filings related to Praxis’ common stock listing on The Nasdaq Global Select Market under the symbol PRAX, shareholder meeting results, and executive compensation or governance matters disclosed in proxy-related documents. As Praxis advances ulixacaltamide, vormatrigine, relutrigine and elsunersen, its periodic and current reports are expected to discuss clinical progress, regulatory designations, risk factors and use of proceeds from financings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each PRAX filing. Real-time updates from EDGAR, combined with accessible explanations of complex disclosures, make this page a practical starting point for analyzing Praxis Precision Medicines’ regulatory and financial reporting history.
Praxis Precision Medicines, Inc. reported an insider tax-withholding transaction by its Principal Accounting Officer, Lauren Mastrocola. On 01/12/2026, 344 shares of common stock were withheld by the company at a price of $275.74 per share to cover tax obligations arising from the vesting of previously reported restricted stock units. After this automatic withholding, Mastrocola directly beneficially owns 13,445.656 shares of Praxis common stock. The filing is a routine Form 4 disclosure of this non-open-market transaction.
Praxis Precision Medicines Chief Operating Officer Megan Sniecinski reported an automatic withholding of 885 shares of common stock on January 12, 2026. The issuer retained these shares to satisfy tax withholding obligations that arose when previously reported restricted stock units vested, rather than through an open-market sale.
After this tax-related withholding, Sniecinski beneficially owns 28,530 shares of Praxis Precision Medicines common stock, held directly.
Praxis Precision Medicines officer reports tax-related share withholding. General Counsel and Secretary Alex Nemiroff reported that on 01/12/2026, 768 shares of Praxis Precision Medicines common stock were withheld by the company at a price of $275.74 per share. According to the footnote, these shares were withheld by the issuer to cover tax obligations arising from the vesting of previously reported restricted stock units, rather than sold in an open-market transaction. After this withholding, Nemiroff directly beneficially owns 25,932.667 shares of Praxis common stock.
Praxis Precision Medicines, Inc. chief financial officer Kelly Timothy Edwin reported a Form 4 transaction involving company common stock. On January 12, 2026, 943 shares of Praxis common stock were withheld by the issuer at a price of $275.74 per share to cover tax withholding obligations tied to the vesting of previously reported restricted stock units. After this tax-related withholding, Edwin beneficially owned 31,046 shares of Praxis common stock in direct ownership.
Praxis Precision Medicines, Inc. reported insider equity transactions by Principal Accounting Officer Lauren Mastrocola. On January 8, 2026, she received 3,750 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. She was also granted a stock option for 7,500 shares of common stock at an exercise price of $294.38 per share, vesting over four years with 25% on January 8, 2027 and the remainder in 36 monthly installments. On January 10, 2026, 367 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations related to vesting of previously reported restricted stock units, leaving her with 13,789.656 shares of common stock held directly.
Praxis Precision Medicines, Inc. (PRAX) Chief Operating Officer Megan Sniecinski reported new equity awards and a tax-related share withholding. On January 8, 2026, she was granted 9,625 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. Also on that date, she received a stock option for 7,700 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 monthly installments.
On January 10, 2026, 1,087 shares of common stock were withheld at a price of $288.45 per share to cover tax obligations tied to previously reported restricted stock unit vesting. After these transactions, she directly held 29,415 shares of common stock and 7,700 stock options.
Praxis Precision Medicines’ General Counsel and Secretary, Alex Nemiroff, reported new equity awards and a tax-related share withholding. On January 8, 2026, he was granted 6,875 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of the January 8, 2026 vesting start date.
On the same date, he also received a stock option for 5,500 shares at an exercise price of
Praxis Precision Medicines’ Chief Financial Officer Timothy Edwin Kelly reported new equity awards and a tax-related share withholding. On January 8, 2026, he received 8,800 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. That same day he was granted a stock option for 7,040 shares at an exercise price of
Praxis Precision Medicines, Inc. Chief Executive Officer and director Marcio Souza reported new equity awards and related share activity. On January 8, 2026, he was awarded 27,640 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on January 8, 2026. That same day, he received a stock option for 22,110 shares of common stock at an exercise price of $294.38, vesting 25% on January 8, 2027 and the remaining 75% in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 4,252 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations on previously reported RSU vesting. After these transactions, he directly beneficially owned 76,890 shares of common stock, 22,110 stock options, and indirectly held 2,600 shares through his spouse.
Praxis Precision Medicines director reports no share ownership
Praxis Precision Medicines, Inc. director Arbuckle Stuart A filed an initial insider ownership report. The filing states that no securities of Praxis Precision Medicines are beneficially owned by the reporting person as of the event date of January 8, 2026. The form is filed by a single reporting person and is signed by an attorney-in-fact, supported by a power of attorney.
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
What is the market cap of Praxis Precision Medicines (PRAX)?
